{"schema_version":"secwatch.filing_event.v1","accession":"0001562762-24-000036","form_type":"8-K","ticker":"CHE","cik":"0000019584","company_name":"CHEMED CORP","filed_at":"2024-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.374102+00:00","generated_at":"2026-06-05T13:22:02.093019+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Chemed Q4 revenue up 7.2% to $585.9M; VITAS adjusted EBITDA +61.6%; FY2024 guidance issued","bullets":["GAAP diluted EPS $5.90 (+42.9% YoY); adjusted diluted EPS $6.60 (+35.0% YoY).","VITAS net patient revenue $350M (+13.6%), ADC 19,352 (+11%), adjusted EBITDA excl. Medicare Cap $83.3M (+61.6%), margin 23.7%.","Roto-Rooter revenue $235.9M (-1.1%), adjusted EBITDA $64.9M (-6.4%), margin 27.5% (down 154 bps).","FY2024 adj. EPS guidance $23.30-$23.70 vs 2023 adj. EPS $20.30; VITAS rev growth 9-9.8%, Roto-Rooter rev growth 3.5-4%.","Cash $264M, no debt; repurchased 79,512 shares for $46M at $579.09 per share."],"urls":{"canonical":"https://secwatch.observer/filing/0001562762-24-000036","json":"https://secwatch.observer/filing/0001562762-24-000036.json","markdown":"https://secwatch.observer/filing/0001562762-24-000036.md","text":"https://secwatch.observer/filing/0001562762-24-000036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/19584/000156276224000036/0001562762-24-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/19584/000156276224000036/che-20240227x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T13:22:02.093019+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c73602bfb02a4889ae7a6d25f1be20d7b3c56f5e","claim":"CHEMED CORP reported the quarter ended December 31, 2023 results: revenue $585.9 million, EPS $5.90.","evidence_excerpt":"Retention Program was $19.6 million and $14.6 million, respectively.  Results for Quarter Ended December 31, 2023  Consolidated operating results: · Revenue increased 7.2% to $585.9 million · GAAP Diluted Earnings-per-Share (EPS) of $5.90, an increase of 42.9% · Adjusted Diluted EPS of $6.60, an increase of 35.0%  VITAS segment operating results: · Net Patient","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/19584/000156276224000036/0001562762-24-000036-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended December 31, 2023"},{"label":"Revenue","value":"$585.9 million"},{"label":"EPS","value":"$5.90"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}